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Future  system  for  the  free  movement  of  medicinal  products 
in  the  European  Community 
Amendment  to  the  proposal  for  a  SYN  309 
COUNCIL  REGULATION  (EEC) 
layirig  down  Community  provisions  for  the  authorization  and 
supervision of  medicinal  products  for  human  and  veterinary  use 
and  establishing  a  European  Agency  for  the  Evaluation  of 
Medicinal  Products 
Amendment  to  the  proposal  for  a 
COUNCIL  DIRECTIVE 
amending  Directives  65/65/EEC,  75/318/EEC  and  75/319/EEC 
in  respect  of  medicinal  products 
Amendment  to  the  proposal  for  a 
COUNCIL  DIRECTIVE 
amending  Directives  81/851/EEC  and  81/852/EEC 
in  respect  of  veterinary medicinal  products 
(presented  by  the  Commission  pursuant  to 
Article  149  (3)  of  the  EEC  Treaty) 
SYN  310 
SYN  311 - ~  -
EXPLANATORY  MEMORANDUM 
Following  the  first  readings  by  the  Eurpoean  Parliament  during 
its part  session of  June  1991,  the  Commission  has  decided  in 
accordance  with  Article  149,  paragraph  3  of  the  EEC  Treaty  to 
amend  the  following  pr~posals:  (1) 
1.  Proposal  for  a  Council  Regulation  <EEC)  laying-down 
Community  provisions  for  the  authorization  and  supervision 
of  medicinal  products  for  human  and  veterinary use  and 
establishing  a  European  Agency  for  the  Evaluation  of 
Medicinal  Products  (SYN  309); 
2.  Proposal  for  a  Council  Directive  amending  Directives 
65/65/EEC,  ?5/318/EEC  and  ?5/319/EEC  in  respect  of 
medicinal  products  <SYN  310); 
3.  Proposal  for  a  Council  Directive  amendinr Directives 
81/851/EEC  and  81/852/EEC  in  respect  of  veterinary 
medicinal  products  (SYN  311): 
1.  O.J.  N°  C  330,  31.12.1990;  COM  (90)  283  final - 2  -
The  Commission  has  decided  to  accept: 
- a  series  of  amendments  which  would  appear  to  improve  the 
operation  or  the  transparency  of  the  centralized  and 
decentralized  Community  authorization  procedures  or  improve 
the  safeguards  for  ind~stry contained  in  those  procedures; 
- amendments  which .encourage  greater  cooperation  between  the 
Community  and  the  World  Health  Organisation  in  relation  to 
pharmacovigilance; 
- three  a~en4ments which  provide  that  medicinal  products 
consisting  of  genetically modified  organisms  may  only  be 
authorized  for  use  in  the  Commupity  if they  satisfy  the 
substantive  requirements  of  Council  Directive  90/220/EEC  of 
23  April  1991  on  the  deliberate  release  into  the  environment 
of  genetically modified  organisms  (2) 
- that  part  of  amendment  168  which  ~llows  the  European 
Parliament  to  nominate  two  representatives  to  the  Management 
Board  of  the  Agency. 
2.  O.J.  No  L  117,  8.5.1990,  p  15 - 3  -
H.owever,  the  Commission  has  decided  not  to· accept: 
- those  amendments  which  would  substantially  change  the 
balance  between  the  centralized  and  decentralized 
procedures,  or  which  would  attribute  major  additional  tasks 
to  the  Agency  in  the  early  years  of  its operation: 
- those  amendments  which  seek  to  amend  the  substintive  rules 
for  the  authorization of  medicinal  products  as  they  have 
developed  since  1965; 
- those  amendments  which  would  lay  down  unduly  strict rules  of 
a  procedural  nature  which  are  not  found  in  the  legislation of 
any  Member  State: 
- the  other  amendments  of  an  institutional  nature  which  would 
reduce  the  rights  of  Member  States,  or  of  the  Commission. 
In  summary  therefore,  the  Commission  has  accepted,  in  whole  or 
in  part,  67  of  the  155  amendments  voted  by  Parliament. 1. 
- 4  -
Amendment  to  the  proposal  for  a  SYN  309 
COUNCIL  REGULATION  (EEC) 
laying  down  Community  provisions  for  the  authorization  and 
supervision  of  medicinal  products  for  human  and  veterinary  use 
and  establishing  a  European  Agency  for  the  Evaluation  of 
Medicinal  Products  · 
Original  Text  Amendment  to  the  proposal 
Visas  and  recitals  1  - 3  unchanged 
Fourth  recital 
Whereas  in  the  interests  of  public 
health  it  is  necessary  that 
decisions  on  the  authorization  of 
such  medicinal  products  should  be 
~ased  on  the  objective  scientific 
criteria  of  the  quality,  the  safety 
and  tho  efficacy  of  the  medicinal 
product  concerned  to  the  exclusion 
of  economic  or other considerations, 
whereas,  however,  Member  States 
should  exceptionally  be  able  to 
prohibit  the  use  on  their  territory 
of  medicinal  products  for  human  use 
which  infringe  objectively  defined 
concepts  of  oublic  order  or  public 
morality;  whereas  moreover  a 
veterinary  medicinal  product  may 
not  be  authorized  by  the  Comm·unity 
if  its  use  would  contravene  the 
::u~os  and  e>b1ectives  laid  down  by 
tho  Community  within  t)1e _ frame_',:-!ork 
?i. the  common  aqricu_ltural  oolicY.I 
Recitals  5  -
Twelfth  recital 
Whereas  the  primary  task  of  the 
Agency  should  be  to  provide 
scientific  advice  of  the  highest 
possible  quality  to  the  Community 
institutions  and  the  Member  Stmtea 
for  thQ  exercise  of  the  powers 
conferred  upon  them  by  Community 
legislation  in  the  field  of 
medicinal  products  in  relation  to 
the  authorization and  supervision of 
medicinal  products, 
Fourth recital 
Whereas  in  the  interests  of  public 
health  ~nd  the  consumers  of 
medicinal  product£  it  is  necessary 
tllat  decisions  on  the  authorization 
of  such medicinal  ptoducta  should  be 
baaed  on  the  objective  scientific 
criteria  of  the  quality,  the  safety 
and  tho  efficacy  of  the  medicinal 
product  concerned  to  the  exclusion 
of  economic  or other considerationst 
whereas,  however,  Member  States 
should  exceptionally  be  able  to 
prohibit  the  use  on  their  territory 
of  medicinal  products  for  human  usa 
which  infringe  objectively  defined 
concepts  of  oubl ic  order  or  public 
morality;  whereas  moreover  a 
veterinary  medicinal  product  may 
not  be  authorized  by  the  Community 
if  its  use  ~ould  contravene  the 
::u~os  and  objectives  laid  down  by 
tho  Community  within  the.  framework 
of  the  common  agricultural  oolic~r 
11  unchanged 
Twelfth  recital 
Whereas  the  primary  task  of  the 
Agency  should  be  to  provide 
scientific  advice  of  the  highest 
possible  quality  to  the  Community 
institutions  and  the  Member  States 
for  the  exercise  of  the  powers 
conferred  on  them  by  Communi.ty 
legislation  in  the  field  of 
medicinal  products  in  relation  to 
the authorization  and  supervision of 
medicinal  products  for  the  p~rpoee~ 
Qi___.  protecting 
consumers'  interests  and  ensuring 
maximum  transparency of  procedures; - 5  -
Original  Text 
Amendment  to  the  proposal 
Recitals  13  - 17  unchanged 
Eighteenth  recital 
Whereaa  the  Agency,  working  in  close 
cooperation  with  the  Convniaaion, 
ahould  alec  be  entruatad  with  the 
taak ot coordinating the discharge of 
the  various  supervisory 
responsibilities of  Member  States and 
in  particular  monitoring  the  respect 
ot  good  manufacturing practices,  good 
laboratory  practices  and  good 
clinical practices; 
Eighteenth recital 
Whereas  the Agency;  working  in close 
cooperation  with  the  Convnission, 
should  also  be  entrusted  with  the 
~ task  of  coordinating  the  discharge 
of  the  various  supervisory 
responsibilities  of  Member  States 
and  in  particular  the  provision  of 
information  concerning  medicinal 
products  and  monitoring  the  respect 
of  good  manufacturing  practices, 
good  laboratory  practices  and  good 
clinical practices; 
Nineteenth  recital  unchanged 
n  O.J.  N°  L  117,  8.5.1990,  p.  15 
Twentienth  recital  (new) 
Whereas  risks .to  the 
environment  may  be  associated 
with  medicinal  products 
containing  or  consisting  of 
genetically modified 
organisms;  whereas  therefore 
it  is  necessary  to  provide  for 
an  environmental  risk 
assessment  of  such  products, 
similar  to  that  provided  for 
by  Directive  90/220/EEC  on  the 
deliberate  release  into  the 
environment  of  genetically 
modified  organisms  (9), 
together  with  the  assessment 
of  the'·guality,  safety  and 
efficacy of  the  product 
concerned  within  a  single 
Community  procedure: f2) 
- 6  -
Original  Text  Amendment  to the  proposal 
Articles  1  - 5  unchanged 
Article  6  Article  6 
Article  6,  paragraph  1,  unchanged 
Article  6  (2) 
2.  The application shall also be accompanied by the fee 
payable  to  the  Agency  for  the  examination  of  the 
application. 
Article  6  (3) 
3.  The  Agency  shall  ensure  that  the  opinion  of  the 
Committee is given within 210 days of the receipt of a valid 
application. 
Article  6  (2) 
2.  In  the  case  of  a  medicinal 
product  containing  or  consisting 
of  genetically modified  organisms 
within  the  meaning  of  Article  2 
paragraphs  1  and  2  of  Directive 
90/220/EEC  on  the  deliberate 
release  into  the  environment  of 
genetically  modified  organisms, 
the  application  shall  also  be 
accompanied  by; 
- a  copy  of  the  written  consent, 
from  the  competent  authority, 
to  the  deliberate  release  of 
the  genetically modified 
organisms  for  research  and 
development  purposes  provided 
for  in  Article  6(4)  of 
Directive  90/220/EEC: 
- the  complete  technical  dossier 
supplying  the  information 
requested  in  Annexes  II  and  III 
of  Directive  90/220/EEC  and  the 
environmental  risk  assessment 
resulting  from  this  information. 
Articles  11  to  18  of  Directive 
90/220/EEC  shall  not  apply  to 
medicinal  products  for  human  use 
containing  or  consisting  of 
genetically  modified  organisms. 
Article  6(3) 
~The application  shall  also  be 
accompanied  by  the  fee  payable  to 
the  Agency  for  the  examination  of 
the  application. O.riginal  Text 
Article  6  (4) 
4.  The Agency shall, in consultation with Member States, 
the  Commission  and  Interested  parties,  draw up  detailed 
~uidance  on the form in which applications for authorization 
Jre to be presented. 
- 7 -
Amendment  to  the  proposal 
Article  6  (4) 
4.  The  Agency  shall  ensure  that 
the  opinion  of  the  Committee  is 
given  within  219  days  of  the 
receipt  of  a  valid  application. 
In  the  case  of  a  medicinal 
product  containing  or  consisting 
of  genetically modified 
organisms.  the  opinion  of  the 
Committee  shall  take  account  of 
the  environmental  safety 
requirements  laid  down  by 
Directive  90/220/EEC. 
Article  6  (5)  (new) 
~The Agency  shall,  in 
consultation with  Member  States, 
the  Commission  and  interested 
parties,  draw  up  detailed 
guidance  on  the  form  in  which 
applications  for  authorization 
are  to  be  presented. 
Articles  7  - 9  unchanged Original  Text 
Article  10  (1) 
1.  Within  30  days  o!  the  receipt  o! 
the  opinion,  the  Commission  shall 
prepare  a  draft  of  the  Decision  to 
be  taken  in  respect  of  the 
application,  takina  into  account  the 
ob1ectives  of  Community  oolJcies  and 
consi~er-ina  alJ,.  th~>  reJ.evant 
information.  In  the  event  of  a 
draft  Decision  which  envisages  the 
granting  of  a  marketing 
authori%ation,  the  documents 
referred  to  in  pointe  (a),  (b)  and 
(c)  of Article 9(3)  shall  be  annexed. 
The  Commiaaion  ahall  transmit  .the 
draft  Deciaion  to  the  Member  States 
and  to the  applicant. 
The  Commission 
detail  the 
shall  explain  in 
reasons  for 
between  the 
any 
draft  differences 
Decidon  and  the  opinion  of  the 
committet. 
Article  10  (2) 
2.  The  Commission  shall  adopt  the 
Decision  to  be  taken  in  respect  of 
the  application  unless,  within  30 
days,  it  has  received  a  reasoned 
request  from  a  Member  State  to 
reconsider  the  matter.  The  Member 
state concerned  shall also transmit  a 
copy  of  it3  request  to  the  other 
Member  States  and  the  applicant 
within the  same  time  limit. 
-a  Amendment  to  the  proposal 
Article  10·(1) 
1.  Within  30  days  of  the  receipt  of 
the  opinion,  the  Commission  shall 
prepare  a  draft  of  the  Decision  to 
be  taken  in  respect  of  the 
application,·  takina  into  account  the 
ob1ectives  of  Commun~tv policies  and 
consi~erina  al}.  th~>  reJ.evant 
information.  In  the  event  of  a 
draft  Decision  which  envisages  the 
granting  of  a  marketing 
authori%ation,  the  document• 
referred  to  in  pointe  (a),  (b)  and 
(c)  of Article 9(3)  shall be  annexed. 
The  Commisaion  shall  transmit  the 
dratt  Decision  to  the  Member  States 
and  to the applicant. 
If,  exceptionally,  the  Commission 
intends  to  draw  up  a  draft  Decision 
which  differs  from  the  opinion  of 
the  Camlittee,  the  Commission  shall 
explain  in  detail  the  reasons  for 
any differences. 
Article  10  (2) 
2.  The  Commission  shall  adopt  the 
Dec is  ion  to  be  taken  in  respect  of 
the  application  unless,  within  30 
days,  it  has  received  a  reasoned . 
request  from  a  Member  State  to 
reconaider  the  matter.  The  Member 
state concerned  shall also transmit  a 
copy  of  it~  request  to  the  other 
Member  States  and  the  applicant 
within the  same  time  limit. 
The  Member  State  requesting 
reconsideration  shall  provide  a 
detailed  justification  based  on 
scientific  evidence  or  Community 
Article  10,  paragraphs  3  and  4  unchanged 
Article  10  (5),  new 
The  Agency  shall,  upon  reque.;t, 
inform  any  interested  person  of  the 
contents of  its final  opinion. - 9-
Original  Text  Amendment  to  the  proposal 
Article  11  unchanged 
Article  12  (1) 
1.  Without  prejudice  to  Article 6  of  Directive 
65/65/EEC, a  marketing  authorization  which  has  been 
granted in accordance with the procedure laid down in this 
Regulation shall apply throughout the Community. It shall 
confer the same rights and obligations in each of  the Member 
States as a marketing authorization granted by that Member 
State  in  accordance  with  Article 3  of  Directive 
65/65/EEC. 
Article  12  (1) 
1.  Without  prejudice  to  Article 6  of  Directive 
65 I 651 EEC,  a  marketing  authorization which  has  been 
granted in accordance with the procedure laid down in this 
Regulation shall apply throughout the Community. It shall 
confer the same rights and obligations in each of  the Member 
States as a marketing authorization granted by that Member 
State  in  accordance  with  Article 3  of  Directive 
65/65/EEC. 
The  authorized  medicinal 
products  shall  be  entered  in  the 
Community  Register  of  Medicinal 
Products  and  they  shall  be  given  a 
number  which  must  appear  on  the 
packaging. 
Article  12  (2)  unchanged 
Article  12  (3) 
J.  An  announcement  that 
~uthorization  has  been  granted  shall 
be  publiahed  for  information 
purpoees  in  the  Official  Journal  of 
the  European  Communities. 
Article  12  (3) 
3.  Notification  of  marketing 
authorization  shall  be  published  in 
the Official Journal  of  the European 
Communities,  auoting  the  number  in 
the  Community  Register. 
Article  12  (4)  unchanged 
Article  13  (1) 
1.  Authorization  shall  be  valid  for 
five  years  and  may  be  renewable  for 
five-year  periods,  on  application  by 
the  holder  at  least  three  months 
before  the  expiry date. 
Article  13  (1) 
1.  Authorization  shall  be  valid  for 
five  years  and  may  be  renewable  for 
five-year  periods,  on  application  by 
the  holder  at  least  three  months 
before  the  expiry  date  and  after 
consideration  by  the  Agency  of  a 
dossier  containing  up-to-date 
information  on  pharmacovigilance. Original  Text 
Article  13  (2) 
2.  In  exceptional  circumstances  and  following 
consultation with  the applicant, an  authorization may  be 
granted subject to such conditions as appear necessary  to 
ensure the  protection  of public  health,  including  specific 
obligations to conduct further studies following the granting 
of authorization and specific obligations in  respect of the 
reporting of adverse reactions to the medicinal product. 
-10-
Amendment  to  the  proposai 
Article  13  (2) 
2.  In  exceptional  circumstances  lind 
following  consultation  ~it.h.  the 
appl~cant,  an  authorization  may  be 
granted  subject; 
to  certain  specific  obligations,  to 
be  defined  and  reviewed  annually  by 
the Agency,  to: 
=  conduct  further  studies  following 
the granting of authorization; 
- report  adverse  reactions  to  the 
medicinal  product. 
Such  exceptional  decision~ may  only 
be  adopted  for  objective  and 
verifiable reasons  and  must  be  based 
on  one  of  the  causes  mentioned  in 
Chapter  III  of  Part  III  of  the 
Annex  to Directive 75/318/EEC. 
Some  products  may  be  authorized 
only  for  use  in  hospitals  or  for 
prescription by  specialists. 
Article  13  paragraph  3  unchanged 
Article  14  unchanged 
Article  15  paragraphs  1  - 3  unchanged 
Article  15  (4) 
4.  The  Agency  shall,  ir.  consultation 
with  the  Commission,  adopt 
appropriate  arrangements  for  the 
examination  of  amendments  and 
variation&  to  the  terms  of  a 
marketing authorization. 
Article  15  (4) 
4.  The  Agency  shall,  in 
consultation  with  the  Commission, 
adopt  appropriate  arrangements  for 
the  examination  of  amendments  and 
variations  to  the  terms  of  a 
marketing  authorization.  These 
arrangements  shall  include  a 
notification  system  or 
administrative procedures  concerning 
minor  changes  and  define  precisely 
the concept  of  •a  minor change'. 
Articles  16  and  17  unchanged Original  Text 
Article  18  (1) 
1.  Where the supervisory authorities or the competent 
authorities of any other Member State are of the opinion that 
the  manufacturer or importer from  third countries  is  no 
longer fulfilling the obligations laid down in Chapter IV of 
Directive  7513191EEC,  they  shall  forthwith  inform  the 
Committee and  the Commission, stating their  reasons  in 
detail and indicating the course of action proposed. 
The same shall apply where a Member State considers that 
one of the measures envisaged  in Chapter V of Directive 
7 5 I 319  I EEC should be applied in respect of the medicinal 
product concerned. 
Amendment  to  the  proposal 
Article  18  (1) 
1.  Where  the  supervisory  authorities 
or  the  competent  authoritie6  of  any 
other  Member  State  are  of  the 
opinion  that  the  manufactuce~  or 
importer  from  thir:d  countri  e&  ls  no 
longer:  fulfilling  the  obli.9atlons 
laid  down  in  Chapter  IV  ~f  OLrectlve 
75/319/EI!:C,  they  :;hall  focthwith 
inform  the  commit..tee  and  the 
C()mmiosion, 
detail  and 
stating  their  reasons  in 
indicating  che  cou.o:oo  of 
~ction proposed. 
The  same  shall  apply  where  a  Member 
State  or  the  Commission  considers 
that  one  of  the  measures  envisaged 
in  Chapter  V  or  Chapter  Va  of 
Direcitve  75/319/EEC  should  be 
applied  in  respect  of  the  medicinal 
product  concerned. 
Article  18  paragraphs  2  and  3  unchanged. 
Article  18  (4) 
4.  In  exceotional  casAR,  where  action 
is  urgently  necessary  to  prot&ct 
public  health,  a  Member  State  may 
suapend  the  use  on  its territory of  a 
medicinal  product  which  has  been 
4Uthoriz&d  in  accordance  with  this 
Re~ulation.  It  shall  inform  the 
Cnnuniseion  no  latet:  than  the 
following  working  day  of  the  reasons 
tor  its action.  The  Commission  shall 
immediately  consider  the  reasons 
given  by  the  Member  State  in 
~ccordance with  paragraph  2  and  shall 
I nit late  the  procedure  provided  for 
in  p11ragraph  J. 
Article  18(4) 
4.  In  exceotional  caeesL  where  action 
is  urgently  necessary  to  protect 
?ublic  health,  a  Member  State  may 
su~:~peud  thft  use  on  ita  territory of  a 
::-.edic inal  product  which  has  bee:-1 
dUthoriz&d  in  accordance  with  this 
Rt~~ulation, if it  finds  the  _fo!J.owL~:. 
.11.1  The  zev(·!l." i. tv  of  the  harm  that 
could  be  caused  by  the 
medisJ.lli!l_Rroduct  cannot  await 
the  definitive  decision  of  the 
Com_:n i. s s ion; 
.L:U  There  is  a  1 ikel ihood  that  the 
med~cina!__Q_roduct  will  cause 
~he  succected  harm  during  the 
Commis8ion·~ deliberations; 
( 3)  The  risk  to  patients  currently 
taking  the  medicinal  product 
Q££~_-hor.ed  by  the  removal  of 
the  product  from  the  market· is 
out-weighed  by  the  degree  of 
harm  posed  by  the product. Original  Text 
Article  18  (5)  unchanged 
., 
-12-
Amendment  to  the  proposal 
The  Member  State  in  question  shall 
inform  the  Commission  no. later  than 
the  following  working  day  of  the 
reasons  for  its  action.  It  shall 
also  inform  the  health  authorities 
of  the  other  Member  States.  The 
Commi as ion  sha 11  immediately 
consider  the  reasons  given  by  the 
Member  State  in  accordance  with 
paragraph  2  and  shall  initiate  the 
procedure  provided  for  in  paragraph 
3.  In  such  cases  the  Member  State 
in  question  shall  immediately  take 
the necessary measures to inform the 
eublic. 
Article  18  (6),  new 
The  Agency  shall,  upon  request, 
inform  any  interested  person  of  the 
contents  of  the  Committee's  oeinion 
referred to  in earagraeh 2. 
Articles  19  - 21  unchanged 
Article  22  paragraphs  1  and  2  unchanged 
Article  23 
Each  Member  State  shall  report  any 
suspected  serious  adverse  reaction 
arising  within  ita  ierritory  to  a 
medicinal  product  authorized  in 
accordance  with  this  Regulation  to 
the  Agency  and  the  peraon 
responsible  for  marketing  within  15 
days  of  receipt  of  a  report  from  a 
qualified health care professional. 
Article  22  (3),  new 
The  person  responsible  for marketing 
shall  accomeany  the  records  of 
adverse  reactions  with  an  analysis 
of  the  data  regarding  such 
reactions,  in  order  to  make  them 
easier to understand. 
Article  23 
Each  Member  State shall organize the 
eharmacoviqilance service within its 
territory  according  to  the 
provisions  of  Article  24.  It shall 
report  any  suspected 
serious  adverse  reaction  arising 
within  its territory  to  a  medicinal 
product  authorized  in  accordance 
with  this  Regulation  to  the  Agency 
and  the  person  responsible  for 
marketing  within  15  days  of  re~eipt 
of  a  report  from  a  qualified  health 
care professional. Original  Text 
Article  24 
The  Agency  shall,  in  consultation 
with  Member  States,  the  Commission 
and  interested  parties,  draw  up 
detailed  guidance  on  the  collection, 
verification  and  presentation  of 
adverse  reaction reports. 
-13 
Amendment  to  the  proposal 
Article  24 
The  Commission  shall,  in 
consultation with  the Agency,  Member 
States  and  interested  parties, 
approve  detailed guidance,  common  to 
all  the  Member  States- on  the 
collection,  verification  and 
presentation  of  adverse  reaction 
reports.  These  reports shall  have  a 
format  similar  to  that  used  by  the 
World  Health Organization; 
The  Agency,  in 
consultation  with  the  Member  State~ 
and  the  Commission,  shall  set· up  a 
data-processing  network  for  t.he 
rapid  transmission  of  data  between 
the  competent  Community  authorities 
in  the event  of  an  alert relating to 
faultv  manufacture,  seriou~ 
undesirable  effects  and  other 
pharmacovigilance  data  regardino 
medicinal  products  marketed  in  the 
Community. 
Article  25  unchanged 
Article  25a,  new 
The  Agency  shall  collaborate  wicb 
the  World  Health  Organization  on 
interna  tiona  1  pharmocov igi  lance  and 
shall  take  the  necessary  steps  to 
submit  promptly  to  the  World  Health 
Organization  appropriate  and 
adeguate  information  regarding  the 
measures  taken  in  the  Community 
which  may  hav-:  a  bearing  on  pubi..i.c 
health protection  in third countries 
and  shall  send  a  copy  thereof to the 
Commission  and  the  Member  States. 131 
·- 14  -
Original  Tex.t  Amendment  to  the  proposal 
Article  26  unchanged 
.Ar.t.i cle  27 
.'Ar,ti.i:cJ.e  ~'2:7.,  paragr-aph  '1.,  unchange.d 
Article  2 7  f2) 
2.  The application shall also be accompanied by the fee 
payable  to  the  Agency  for  the  examination  of  the 
application. 
Article  27  (3) 
3.  The  Agency  shall  ensure  that  the  Qpinion  of the 
Committee is given within 210 days·ofthe receipt of.a·valid 
application. 
Article  27  (2) 
2.  'In ·.the -ca·se ·.Of  ;a  :veterinary 
medicinal  product  containing  or 
cons:ist·.ing ·of ·genetically 
mod:i:fied  or..ga·nisms  within  the 
meaning  of Article  2  paragraphs  1 
and  ~2  o·f  D  i·re  c t:i•ve ·  9 0 /2·2·0·1. EEC  on 
the  deliberate  release  ~into ·the 
environment ·of  ~enetically 
modified  organisms,  ~he 
appl'ication -s·hall ·also  be 
accompanied  by; 
- a  copy  o·f  the  writ ten  consent, 
'from  ·the  ·competent  authority, 
to  the  de·libera te  release· of 
the  genetically  modified 
organisms  for  research  and 
devalopment  purposes  ~rovided 
for  in  Article  6(4)  of 
Directive  90/220/EEC; 
- the  com~lete technical  dossier 
supplying  the  information 
regue·s'ted  in  Annexes  I I  and  I I I 
of  Directive '90/220/EEC  and  the 
envjronmental  ri~sk assessment 
re·su~l!t:ing .from  this information. 
Arti.c.les  :lil  to  18 -of 'Direc·t·ive 
90/,220/EEC 'Shall  not 'apply  to 
veterinary .medicinal  products 
:con.taining  or  consi.sti·ng  of 
.geneticaLly  modified -organ'i-s-ms. 
·'A r t.i'c 1 e  27  · ( 3 > 
3.  The  application  shall  also  be 
accompanied  by  the  fee  payable  to 
the  Ag~ncy for  the  examination  of 
the  application. Original  Text 
Article  27  (4) 
4.  The Agency shall, in consultation with Member States, 
the  Commission  and interested parties,  draw  up  detailed 
guidance on the form in which applications for au_thorization 
are to be presented. 
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Amendment  to  the  proposal 
Article  27  (4) 
4.  The  Agency  shall  ensure  that 
the  opinion  of  the  Committee  is 
given  within  210  days  of  the 
receipt  of  a  valid application. 
In  the  case  of  a  veterinary 
medicinal  product  containing  or 
consisting of  genetically 
modified  organisms,  the  opinion 
of  the  Committee  shall  take 
account  of  the  environmental 
safety  requirements  laid  down  by 
Directive  90/220/EEC. 
Article  27  (5)  (new) 
5.  The  Agency  shall,  in 
consultation with  Member  States, 
the  Commission  and  interested 
parties,  draw  up  detailed 
guidance  on  the  form  in  which 
applications  for  authorization 
are  to  be  presented. 
Articles  28  - 30  unchanged - 16-
Original  Text 
Article  31  (1) 
1.  Within  30  days  of the  receipt  of the  opinion.  the 
Commission shall prepare a draft of the Decision 10 be take:: 
in  respect  of  the  application  taking  into  account  the 
objectives  of  Community  policies  and  considering  all 
relevant information. In the event of a draft Decision which 
envisages  the  granting of a  marketing authorization,  the 
documents referred to in points (a), (b), and (c) of Article 30 
(3)  shall  be  annexed.  The Commission  shall  transmit  rhe 
draft Decision to the Member States and to the applicant. · 
The  Commission  shall  explain  in 
detail  the 
differences 
Decision  and 
reasons  for 
between  the 
any 
draft 
the  opinion  of 
committu. 
Article  31  (2) 
2.  The  commission  shall  adopt  the 
Dec ieion  to  be  taken  in  respect  of 
the  application  unlose,  within  30 
days,  it  has  received  a  reasoned 
request  !rom  a  Member  State  to 
reconsider  the  matter.  The  Member 
State concerned  shall also  transmit  a 
copy  of  it:l  request  to  the  other 
.Member  States  and  the  applicant 
within  tho  same  time  limit. 
the 
Amendment  to  the  proposal 
Article  31  (1) 
1.  Within  30 days  of the  receipt of the opinion,  the 
Commission shall prepare a draft of the Decision to be taken 
in  respect  of  the  application  taking  into  account  the 
objectives  of  Community  policies  and  considering  all 
relevant information. In the event of a draft Decision which 
envisages  the granting of a  marketing  authorization,  the 
documents referred to in points (a), (b), and (c) of Article 30 
(3)  shall  be  annexed. The Commission shall  transmit the 
draft Decision to the Member States and to the applicant. 
If,  excep~ionally,  the  Commission 
intends  to  draw  up  a  draft  Decision 
which  differs  from  the  opinion  of 
the  Camtittee,  the  Commission  shall 
explain  in  detail  the  reasons  for 
any  differences. 
Article  31  (2) 
2.  The  Commission  shall  adopt  the 
Decision  to  be  taken  in  respect  of 
the  application  unless,  within  30 
days,  it  has  received  a  reasoned 
request  from  a  Member  State  to 
reconaider  the  matter.  The  Member 
state concerned  shall  also transmit  a 
copy  of  it:1  request  to  the  other 
Member  States  and  the  applicant 
within  the  same  time  limit. 
The  .Member  State  requesting 
reconsideratio!l  shall  provide  a 
detailed  jueti!ication  based  on 
scientific  ev ide  nee  or  Community 
Article  31,  paragraphs  3  and  4  unchanged 
Article  31  (5),  new 
The  Agency  sha  11,  upon  regue.;t, 
inform  any  interested  person  of  the 
content~ of  ite  final  opinion. _17  -
0 r i g i ·D a1  Text  Amendment  to  the  proposal 
Articl~ 3a  unchanged 
Article  33  (1) 
1.  Without  prejudice to Article 4  of Council  Directive 
.. . I . . ./EEC  extending  the  scope  of  Directive. 
81/851/EEC on  the. approximation  of the  laws  of the 
Member States  relating to veterinary  medicinal  products, 
andJaying down additional provisions for immunological 
veterinary medicinal  products,  a  marketing authorization 
which has been granted in accordance with the procedure · 
laid down  in  this  Regulation  shall  apply  throughout the 
Community. It shall confer the same rights and obligations in 
each of the  Member States  as  a  marketing authorization 
granted by that Member State in accordance with Article 4 of 
Directive 81/851/EEC. 
Article  33  (1) 
I.  Without· prejudice. to ·Article .4 ·of<' Council  Directive 
... .1 . . ./EEC.  extending:  the  scope'  of  Dirccti\'c 
81185.11 EEC  on.' th'e·  approximarion  of. the·. l:tws  of the 
Member. States -relating: to.  veterinary' medicinal· .products, 
and· laying-.downoadditional ·provisions·. for.·immunological 
veterinary  medicinal. products,  a. marketing ,authorization 
which .has been· granted in  accordance with ·the procedure 
laid  down  in  this  Regulation  shall  apply  throughout  the 
Community. It shall confer rhe.same rights and obligations in 
each  of the  Member Siates  as  a  marketing  authorization 
gr_amed by that Member State in accord:mcewith :\nidc 4 of 
Direcrive SI/851/EEC. 
The  authorized  medicinal 
products·  shall  be.  entered  in  the 
Community  Register  of  Veterinary 
Medicinal  Products  and  they shall be 
given  a  number  which  must  appear  on 
the packaging. 
Article  33  (2)  unchanged 
Article  33  (3) 
3.  An  announcement  that 
authorization  has  been  granted  shall 
be  published  for  information purposes 
in  the·  Official  Journal  of  the 
European  Communities. 
Article  33  (3) 
3.  Notific.ation  of  marketing 
author-ization- shall  be  published  in 
the Official Journal of the European 
Communities,  quoting  the  number  in 
the Community  Register of Veterinary 
Medicinal Products. 
Article  33  (4)  unchanged 
Article  34  (1) 
1.  Authorization  shall  be  valid  for 
five  year•  and  may  be  renewable  for 
five-year  periods,  on  applic&tion  by 
the  holder  at  least  three  months 
before the expiry date. 
Article  34  (1) 
'  ~.  Authori:a~ion ohall be valid for 
five  years  u~d may  be  renewable  for 
five-year  periods,  on  application  by 
the  holder  a~  least  chree  months 
before  the  expiry  date  and  after 
£9n&ideration  by  the  Agency  of  a 
doaeier  contc.Lnina  up-to-da~o 
infortnAtior.  o:-a  phermaccvigilar.ce. Original  Text 
Article  34  (2) 
2.  In  exceptional  circumstances,  and  following 
consuhation with  the applicant, an  authorization mar be 
granted subject to such-conditions as  appear necessary to 
ensure the protection oi.human.or animal health, including 
specific obligations to conduct further studies following the 
granting of authorization and specific obligations in respect 
of the  reporting  of  adverse  reactions. to  the·  veterinary 
medicinal product. 
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Amendment  to  the:proposal 
Article  34  (2) 
2·.  In· exceptiona·l  circumat'ances,  and 
to·l.lowina.  consult(ltion<  with  the 
A col icant,  an:  auth~riz.ation  may  be 
granted  subject  to/ 
certain  specific  obligations 
defined  and  reviewed  annual'ly  by  the 
Agency, 
- t·o  conduct  further  studies 
following  the··  gra.nting  of 
authorization; 
- to  report  adverse 
the  v.et e.r Ln·a ry_ 
products  .. 
.reactions  to 
med.ic ina  1 
Articl~ 34  paragraph· 3  unchang~d· 
Article  35  unchanged 
Article '36  paragraphs  1  - 3  unchanged 
Article  36  (4) 
4.  The  Agency  shall,  in  accordance 
with  the  Commission,  adopt 
appropriate  arrangements  for  the 
examination  of  amendments  and 
variations  to  the  terms  of  a 
marketing  authorization  .. 
Article  36  (4) 
4.  The  Agency  shall,  in  accordance 
with  the  Commission,  adopt 
appropriate  arrangements  for  the 
examination  of  amendments  and 
variations  to  the·  terms  of  a 
marketing  authoriz.·ation.  These 
arrangements'  sha~l  include  a  system· 
of  notification  or  administrative 
procedures  to  take  account  of 
changes  of  minor  importance. 
Articles  37  and  38  unchanged Original  Text 
Article  39  (1) 
1.  Where  the supervisory  authorities or the competent 
authorities of  anv other Member State are of  the opinion that 
the  manufaaur~r or importer from  third countries  is  no 
longer fulfilling the obligations laid down in Chapter V of 
Directive  811851/EEC  they  shall  forthwith  inform  the 
Commirtee and  the Commission, stating their reasons  in 
detail and indicating the course of action proposed. 
The same shall apply where a Member State considers that 
one of the measures envisaged  in  Chapter VI  of Directive 
81/851/EEC should be applied in respect ofthe veterinary 
medicinal product concerned. 
- 19  -
Amendmen!  to  the  proposal 
Article  39  (1) 
1.  Where the supervisory authorities or the competent 
authorities of  any other Member State are of the opinion that 
the  manufacturer or importer  from  third countries  is  no 
longer fulfilling the obligations laid down in Chapter V of 
Directive  81/851/EEC they  shall  forthwith  inform  the 
Committee and the Commission, stating their  reasons  in 
detail and indicating the course of action proposed: 
The  same  shall  apply  where  a 
Member  State  or  the  Commission 
considers  that  one  of  the  measures 
envisaged  in  Chapter  VI  or  Chapter 
VIa  of  Directive  81/851/EEC  should 
be  applied  in  respect  of  the 
veterinary  medicinal  product 
concerned. 
Article  39  paragraphs  2  - 5  unchanged 
Article  39  (6),  new 
~.  The  Agency  shall,  upon  request, 
inform  any  interested  person  of  the 
contents  of  the  Committee's  opinion 
referred to  in  paragraph  2. 
Articles  40  - 42  unchanged 
Article  43  paragraphs  1  and  2  unchanged 
Article  43  (3),  new 
The  person  responsible  for  marketing 
shall  accompany  the  records  of 
adverse  reactlons  with  an  analysis 
of  the  data  regarding  such 
reactions,  in  order  to  make  them 
easier to understand. - 2D- -
Original  Text  Amendment  to  the  prop~sal 
Article  44 
Each  Member  State  shall  report  any 
suspected  serious  adverse  reaction 
arising  within  its  territory  to  a 
veterinary  medicinal  product 
authorized  in  accordance  with  this 
Regulation.  to  the  Agency  and  the 
person  respo~sible  for  marketing 
within  15  days  of  receipt  of  a 
report  from  a  qua  1 i fi ed  he  a 1 th  care 
professional. 
Article  45 
The Agency shall, in_consultation with Member States, the 
Commission  and  interested  parties,  draw  up  detailed 
guidance on the collection, verification and presentation of 
adverse reaction reports to veterinary medicinal products. 
Article  44 
Each  Member  State shall  organize  the 
pharmacovigilance  service within  its 
territory  according  to  the 
provisions  of  Article  45.  It  shall 
report  any  suspected 
serious  adverse  reaction  arising 
within  its  territory  to  a 
veterinary  medicinal  product 
authorized  in  accordance  with  this. 
Regulation.  to  the  Agency  and  the 
person  responsible  for  marketing 
within  15  days  of  receipt  of  a 
report  from  a  qualified  health  care 
professional. 
Article  45 
The  Commission  shall,  in 
consultation with  the Agency,  Member 
States  and  the  interested  parties, 
approve detailed guidance,  common  to 
the  Member  States /  · 
on  the  collection, 
verification  and  presentation  of 
adverse  reaction  reports.  These 
reports.shall  have  a  format  similar 
to  that  used  by  the  World  Health 
Organization 
The  Agency,  in  consultation with  the 
Member  States  and  the  Commission, 
shall  set  up  a  data-processing 
network  for  the  rapid  transmission 
of  data  between  the  competent 
Community  authorities  in  the  event 
of  an  alert  relating  to  faulty 
manu facture,  serious  undesirable 
effects  and  other  pharmacovi gil ance 
data  regarding  medicinal  products 
marketed  in  the  Community. 
Article  46  unchanged Original  Text  Amendment  to  the  proposal 
Article  47  unchanged 
Art'icle  48 
In  .order  to  . promote  the  protection 
of  p.ub 1 i c  he  a 1 th  thr.oughout  the 
Commun.i.ty  .and  the  adoption  .of 
uniform  regulatory  ~ecisions  .based 
on  scientific  criteria  .concerning 
the  ma rke.t  i ng  and  .use  of  medici na  1 
pr.oducts,  the  .objective  -of  the 
Agency  shall  be  to  provide  .the 
Member  S.tates  and  the  Institutions 
of  the  Community  with  .the  bes.t 
possible  scientific  advice  ·on  any 
question  r.ela.ting  to  the  evaluation 
of  the  .quality,  the  .safety  ·or  ·.the 
efficacy  .of  :medicinal  products  for 
human  .or  Neterinary  use  .which  is 
referred  to  it  in  accordance  with 
the  provisions  of  Co~munity 
legislation  relating  to  medicinal 
products. 
In  particular  the  Agency  shall 
~ndertake the  following  tasksa 
Article  47a  (new) 
"The  Agency  shall  collaborate 
with  the ·world  Health  Organization 
on  i nternat  ion  a 1  pharmocovi gfl ance 
.and  shall  take  the  necessary  steps 
_to  submit  promptly  to  the  World 
,Health  Organization  appropriate  and 
adequate  information  regarding  the 
.measures  taken  in  the  Community 
whi'.ch  may  have  a  bearing  on  public 
health  protection  in third countries 
and shall  send  a  copy  thereof to the 
Commission  and ·the-Member  States. 
Article  48 
ln  or.der  .to  promote  ,the  ·protect  1 on 
of  public  health  Jand  consume-rs ·:of 
medicinal  products  .through~ut  the 
Communi 1;y  ,  and  the  adopt  i ob  of 
uniform  regulatory  decisions  ba·sed 
on  sci-entific  criteria  concer'\i ng 
the  marketing  and  rational  use  of 
medicinal  products,  the:objecttve ~f 
the  Agency  shall  be  to  provide  the 
Member  States  and  the  <Institutions 
of  the  . Community  -wi:th  the  best 
possible  scientific  advice  on  -any 
question  relating  to  the  ~valuation 
of  the  qua  1 i ty,  the  safety  or  the 
.  I  eff1cacy  of  medicin<il  _products  for 
human  or  veterinary  use  whi.ch  is 
referred  to  it  in  accordance  with 
the  provisions  of  Community 
legislation  relating  to  ·medicinal 
products. 
In  particular  the  Agency  shall 
undertake  the  following  tasks: -22  -
Original  Text  Amendment  to  the  proposal 
Point  (c) 
Article  48,  points  (a)  and  (b)  unchanged_ 
Point  (c) 
the  continuing  supervision, 
under  pract  i ca  1  conditions  ot: 
use,  of  medicinal  products  which 
have  been  authorized  within  the 
Community  and  the  provision  of 
advice  on  the  measures  nec~ssary 
to  ensure  the  safe  and  effective 
use  of  these  products,  !n. 
particular.  following  the 
evaluation  of  reports  of  adverse 
reactions  (pharmacovigilance); 
the  continuing  supervision, 
under  pract  i ca  1  conditions  of 
use,  of  medicinal  produ~§ 
which  have  been  author1 zed 
within  the  Community  and  'bhe 
provision  of  advice  on  the 
measures  necessary  to  ensure 
the  safe  and  effective  use  ot' 
these  products,  in  particular 
by  collecting,  evaluating  and 
making  available  through  the  a 
database  the  information  on 
adverse  reactions  to  the 
medicinal  products  in question 
(pharmacovigilance); 
Article  48,  points  (d),  (e),  (f)  and  (g)  unchanged 
Point  (h) 
where  necessary,  to  advise  and  to 
allow  for  direct  .dialogue  between 
the  applicant  and  the  Agency  on  the 
conduct  of  the  various  tests  and 
trials  necessary  to  demonstrate  the 
quality,  safety  and  efficacy  of 
medicinal  products. 
Point  (h) 
to  advise  and,  at  thJ  request of the 
applicant,  to  allow  for  direct 
dialogue  between  the  applicant  and 
the  Agency  on  the  conduct  of  the 
various  tests  and  trials  necessary 
to  demonstrate  the  quality,  safety 
and  efficacy of medicinal  products. 
Article  48,  point  (i)  unchanged 
Point  (j),  new 
registering  all  the 
authorizations  for  medicinal 
products  granted  in  the 
European  Community; 
Point  (k),  new 
the  provision  to  health 
profession  a 1 s  of  scientific 
information  on  the  medicinal 
products  authorized  by  this 
Regulation. -23  -
Original  Text  Amendment  to  the  pr_oposa I 
Article  49  unchanged 
Article  50  paragraphs  1  - 3  unchanged 
Article  50  (4)  (new) 
The  opinions  adopted  by 
the  Committees  shall  be 
made  available  to  anyone 
requesting  them. 
Articles  51  and  52  unchanged 
Article  53  paragraphs  1  and  2  unchanged 
Article  53  paragraph  3,  first  four  ~ndents unchanged 
Fifth  indent  (new) 
a  list  of  medicinal  products 
which  have  been  granted 
authorization,  those  for  which 
authorization  has  been  refused 
or  withdrawn  and  those  whose 
in format ion  records  have 
undergone  significant changes. 
Article  53  paragraph  4  unchanged 
Article  53  (5),  new 
Article  54  (1) 
1.  The  management  board  shall  consist  of  two 
representatives  from  each  Member  State  and  two 
representatives of the Commission. One representative shall 
have specific responsibilities relating to medicinal products 
for  human  use  and  one  relating  to veterinary  medicinal 
products. 
The  executive  director  may  not  have 
any  direct  or  indirect  interests  in 
tho  pharmaceutical  industry  which 
would  affect hie  impartiality. 
Article  54  (1) 
1.  The  Management  Board  shall 
consist  of  two  representatives 
from  each  Member  State,  two 
representatives  of  the  Commission 
and  two  representatives  appointed 
by  the  European  Parliament.  One 
representative  shall  have  specific 
responsibilities  relating  to 
medicinal  products  for  human  use 
and  one  relating  to  veterinary 
medicinal  products.  · -24  -
Original  Text  Amendment  to  the  proposal. 
Article  54  paragraphs  2  - 5  unchanged 
Articles  55  -64  unchanged 
Article  65  paragraphs  1  - 4  unchanged 
Article  65  (5),  (new) 
Article  52  (2)  shall  applv 
similarly  to  members  of 
the  Scientific Council. 
Article  66  unchanged 
Article  67 
All  daciaiona  to  grant,  refuse, 
amend,  suspend,  withdraw  or  revoke  a 
markatin9  authorization  which  are 
taken  in  accordance  with  this 
regulation  ahall  state  in  detail  the 
reasons  on  which  they  are  based. 
Such  decisions  ahail  be  notified  to 
the  party  concerned,  who  shall  be 
able  to  exercise  the  remedies 
conferred  upon  him  under  the  EEC 
Treaty. 
Article  67 
All  decisions  to  grant,  refuse, 
amend,  suspend,  withdraw or revoke  a 
marketing  authorization  which  are 
taken  in  accordance  with  this 
regulation shall state in detail the 
reasons  on  which  they  are  based. 
Such  decisions  shall  be  notified  to 
the  party  concerned,  who  shall  be 
able  to  exercise  the  remedies 
conferred  upon  him  under  the  EEC 
Treaty,  in  particular  pursuant  to 
its Article  173. 
Articles  68  and  69  unchanged 
Article  70 
Without prejudice to Article 68, and without prejudice to the 
Protocol on the Privileges and Immunities of the European 
Communities,  each  Member  State  shall  determine  the 
penalties to be applied for the infringement of the provisions 
of  this  Regulation.  The  penalties  shall  be  sufficient  to 
promote compliance with those measures. 
Member States shall forthwith inform the Commission of the · 
institution of any infringement proceedings. 
Article  70 
Without prejudice to Article 68, and without prejudice to the 
Protocol on the Privileges and Immunities of the European · 
Communities,- each  Member  State  shall  determine  the 
penalties to be applied for the infringement of the provisions 
of this  Regulation.  The  penalties  shall  be  sufficient  to 
promote compliance with those measures. 
The  Member  States  shall  also ' 
determine  penal  t lee  to  ensure 
compliance  with  professional  secrecy 
on  the  part  of  the  members  of· the 
Agency  in  accordance  with  the 
provisions  of Article 62. 
Member States shall forthwith inform the Commission of the 
institution of any infringement proceedings. 
Articles  71  - 73  unchanged 
Annex  unchanged -25 
2. 
amending 
Amendment  to  the  proposal  for  a 
COUNCIL  DIRECTIVE' 
Directives  65/65/EEC,  75/318/EEC  and 
in  respect  of  medicinal  products 
SYN  310 
75/319/EEC 
Original  Text 
Visas  and  recitals 
Third  recital 
Whereae  in  the  interests  of  public 
health  ;it  is  necessary  that 
decision&  on  the  authorization  to 
place  medicinal  products  on  the 
market  be  exclusively  based  on  the 
criteria  of  quality,  safety  and 
efficacyt  whereas  these  criteria 
have  been  extensively  harmonized  by 
Directive  65/65/EEC_  of  26  January 
1965  on  tho  approximation  of 
provisions  laid  down  by  law, 
regulation  or  administrative  action 
relating  to  medicinal  products,  as 
last  amended  by  Directive 
89/381/EEC,  and  by  Directive 
75/319/EEC,  and  by  Council 
Directive  75/3~8/EEC of  20  May  1975 
on  the  approximation  of  the  laws  of 
the  Hember  States  relating  to 
analytical,  pharmaco-toxicological 
and  clinical  standards  and  protocols 
in  respect  of  the  testing  of 
medicinal  products,  as  last  amended 
uy  Directive  89/341/EEC;  whe4eas, 
however,  Member  States  should 
exceptionally  be  able  to  prohibit 
the  use  on  their  territory  of 
modicinal  products  which  infringe 
objectively  defined  concepts  of 
public order or public morality; 
Amendment  to  the  proposal 
1  and  2  unchanged 
Third  recital 
Whereas  in  the  interests  of  public 
health  ~nd  consumers  of  medicinal 
products  it  is  necessary  that 
decisions  on  the  authorization  to 
place  medicinal  products  on  the 
market  be  exclusively  based  on  the 
criteria  of  quality,  safety  and 
efficacy;  whereas  these  criteria 
have  been  extensively  harmonized  by 
Directive  65/65/EEC  of  26  January 
1965  on  the  approximation  of 
provisions  laid  down  by  law, 
regulation  or  administrative  action 
relating  to  medicinal  products,  as 
laot  amended  by  Directive 
89/381/EEC,  and  by  Directive 
75/319/EEC,  and  by  Council 
Directive  75/318/EEC  of  20  May  1975 
on  the  approximation  of  the  laws  of 
tho  Member  States  relating  to 
analytical,  pharmaco-toxicological 
and clinical  standards  and  protocols 
in  redpect  of  the  testing  of 
medicinal  products,  as  last  amended 
by  Directive  89/341/EEC;  whereas, 
however,  Hember  States  should 
exceptionally  be  able  to  prohibit 
the  use  on  their  territory  of 
medicinal  products  which  infringe 
objectively  defined  concepts  of 
public  ceder or public morality; 
New  recital  inserted after 
third recital 
1-lher.eo:a_~;  ____  t_here  alreadv  exist  iQ 
Cof!lmunlly_ .!_l!.w  adequate rules  for  the 
~.!J!.Sl_t;,lon_  and  monitoring  of 
rr.e~i,~j._f1~.1 __ products  layinq  down 
maximum  levels  of  quality,  safety 
and  eJ.J.ica_£Y.'  and  allowing the mutual 
!~~qflit~~ of  meaeures  taken  by  the 
authoi;).t!.!t!L__in  the  Member  States 
wi~t!..._r~g~~si  to medicinal  products; 
Remaining  recitals  unchanged - 26  -
Original  Text  Amendment  to  the  proposal 
Article  1  (1),  (Directive  65/65/EEC,  Article  3) 
No  medicinal  product  may  be  placed 
on  the  market  ot  a  Member  State 
unl•••  an  authorization  haa  been 
1ttutd by  tht competent  authority of 
that  Htmbtr  State  or  by  the 
community. 
No  medicinal  product  may  be  placed 
on  the  market  of  a  Member  State 
unless  an  authorization  has  been 
obtained  in  accordance  with 
Community  rules. 
Article  1(2)  unchanged 
Article  1  (3)  (Directive  65/65/EEC,  Article  4b) 
Third  paragraph,  new 
Before  a  medicinal  product  is placed 
on  the  market  the  competent 
authorities  shall  forward  to  the 
European  Agency  for  the  Evaluation 
of  Medicinal  Products  a  copy  of  the 
decision  together  with  the  sununary 
of  the  prod.uct  characteri_stic_2 
referred  to  in  this  Article.  The 
Agency  shall  give  the  authorized 
medicinal  product  a  European 
Register  number  which  shall  be 
marked  on  the packaging. 
Article  1  (4)  unchanged 
Article  1  (5)  (  Directive  65/65/EEC  Article  7(1Q 
1.  Member  States  shall  take  all 
appropriate  measures  to  ensure  that 
the  procedure  for  granting  an 
authorizlltion  to  place  a  medicinal 
product . on  the  market  is  completed 
withir.  210  days  of  the  date  of 
submitting the application. 
1.  Member  States  shall  take  all 
appropriate  measures  to  ensure  that 
the  procedure  for  granting  an 
authorization  to  place  a  medicinal 
product  on  the  market  is  co;npleted 
within  140  days  of  the  date  of 
submitting tho application. 
paragraph  2  unchanged 
Article  1  (6)  and  (7)  unchanged Original  Text  Amendment  to  the  proposal 
Article  1  (8),  (Directive  65/65/.EEC,  Article  10) 
1.  Authorization  shall  be  valid  for 
five  years  and  may  be  renewable  for 
five-year periods,  on  application  by 
the  holder  at  least  three  months 
before  the expiry date. 
2.  In  exceptional  circumstances~  and 
followina  consultation  with  the 
applicant,  an  authorizat1on  may  be 
granted  subject  to  such  conditions 
as  appear  necessary  to  ensure  the 
protection  of  public  health, 
including  specific  obligations  to 
conduct  further  studies  following 
the  granting  of  authorization  and 
specific  obligations  in  respect  of 
the  reporting  of  adverse  reactions 
to  the  medicinal  product. 
1.  Authorization  shall  be  valid  for 
five  years  and  may  be  renewable  for 
five-year  periods,  on  application  by 
the  holder  at  least  three  months 
before  the  expiry  date  and  after 
consideration 
dossier  containing 
of  a 
up-to-date 
information  on  pharmacovigilance. 
2.  In  exceptional  circumstances~  and 
followina  consultation  with  the 
applicant,  an  authorizat1on  may  be 
granted  subject 
to  certain  specific  obligations, 
including: 
the  carrying  out  of  further 
studies  following  the  granting 
of authorization; 
the  not  i fi cat  ion  of  adverse 
reactions  to  the  medicinal 
product. 
These  decisions  shall  be  taken  in 
accordance  with  the  prov1s1ons  of 
Chapter  I I I,  Part  I I I  of  the  Annex 
to ·Directive  75/318/EEC. 
Article  2  unchanged 
Article  3  (1)  (Directive  75/319/EEC,  Chapter  Ill) 
Articles  8  - 11,  proposal  unchanged 
Article  12,  first  par~graph 
The  Member  States  or  the  Commission 
may,  in  specific  cases  where  the 
interests  of  the  Convnuni ty  are 
involved,  refer  the  matter  to  the 
Committee  for  the  application of the 
procedure  laid  down  in  Article  13 
before  reaching  a  decision  on  a 
request  for  a  marketing 
authorization  or  on  the  suspension 
or  revocation  of  an  authorization, 
or  on  any  other  amendment  to  the 
terms  of  a  marketing  authorization 
which  appears  necessary,  in 
particular  to  take  account  of  the 
information  collected  in  accordance 
with  Chapter Va  of this Directive. 
The  Member  States,  the Commission  or 
the  applicant·  himself  may,  in 
specific  cases  where  the  interests 
of  the  Community  are  involved, 
refer  the  matter  to  the  Committee 
for  ·the  application  of  the 
procedure  laid  down  in  Article  13 
before  reaching  a  decision  on  a 
request  for  a  marketing 
authorization  or  on  the  suspension 
or  revocation  of  an  authorization, 
or  on  any  other  amendment  to  the 
terms  of  a  marketing  authorization 
which  appears  necessary,  in 
particular  to  take  account  of  the 
1  nformat ion  collected  in  accordance 
with  Chapter  Va  of this Directive. - 28  -
Original  Text  Amendment  to  the  proposal 
Article  12  paragraphs  2  and  3  unchanged 
Article  13  unchanged 
Article  14  paragraphs  1  - ~  unchanged 
Article  14  paragraph  6,  new 
6.  The  procedure  pursuant  to 
Articles  8  to  14  shall  not  apply  in 
the  instances  covered  by 
Ar.tlcle 9(2)  of  Directive  on 
homeopathic  medicinal  product  a 
CCOMC90>  0072  final- SYN  251). 
Article  15  unchanged 
Article  15a 
1.  Where  a  Member  State  considers 
that  the  amendment  of  the  terms  of a 
marketing  authorization  which  has 
been  granted  in  accordance  with  the 
provisions  of  this  chapter  or  its 
suspension  or  withdrawal  is 
necessary,  the  Member  State 
concerned  sha  11  forthwith  refer  the 
matter  to  the  Cnrnmittee  for  the 
app  1 i cation  of  the  procedures  1 aid 
down  in  Articles  13  and  14. 
2.  In  excent ion  a 1  cases,_  where 
action  is  urgently  necessary  to 
protect  public  health,  until  a 
definitive  decision  is  adopted,  a 
Member  State ·may  suspend  the  use  of 
the  medicinal  product  concerned  on 
its  territory.  It shall  inform  the 
Commission  no  1 ate  r  than  the 
following  working  day  of the  reasons 
for  its actions. 
1.  Where  a  Member  State  considers 
that  the  amendment  of the  terms  of  a 
marketing  authorization  which  has 
been  granted  in.accordance  with  the 
provisions  of  this  chapter  or  its 
suspension  or  withdrawal  is 
necessary,  the  Member  State 
concerned  shall  forthwith  refer  the 
matter  to  the  CommitteP  for  the 
application  of  the  procedures  laid 
down  in Articles  13  and  14. 
2.  In  exceptional  cases:_  where 
action  is  urgently  necessary  to 
protect  public  health,  until  a 
definitive  decision  is  adopted,  a 
Member  State  may  suspend  the  use  of 
the  medicinal  product  concerned  on 
its  territory  if it finds  the  following: 
(1)  The  severity  of  the  harm  that 
could  be  caused  by  the  medicinal 
product  cannot  await  the  definitive 
decision of the  Commission; 
(2)  There  is  a  likelihood  that  the 
medicinal  product  will  cause  the 
suspected  harm  during  the 
Commission's  deliberations; -29  -
Original  Text  Amendment  to  the  proposal 
(3)  The  risk  to  patients  currently 
taking  the  medicinal  product 
occasioned  by  the  removal  of  the 
product  from  the  market  is  out-
weighed  by  the degree of harm  caused 
by  the  product  itself. 
The  Member  State  concerned  shall 
inform  the  Commission  no  later  than 
the  following  working  day  of  the 
reasons  for  its actions. 
Article  15b  unchanged 
l •  The  Agency 
annual  report 
the  procedures 
Chapter. 
a hall 
on  the 
laid 
Article  15c  paragraph  1 
publish  !.!! 
operation  of 
down  in  this 
l.  The  Agency  shall  publish  _i! 
biennial  report  on  the  operation  of 
the  procedures  laid  down  in  this 
Chapter  and  shall  forward  it  for 
information  to  the  European  1 
Parliament  and  the Council. 
Article  15c  paragraph  2  unchanged 
Article  3  (2)  unchanged 
Article  3  (3)  (Directive  75/319/EEC  Article  29a) 
I 
In  order  to  ensure  the  adoption  of 
appropr late  regulatory  decisions 
concerning  the  continued 
authorization  of  medicinal  products 
within  the  Community,  having  regard 
to  information  obtained  about 
adverse  react ions  to  medicinal 
products  under  practical  conditione 
of  use,  Member  States  shall 
eetablieh  a  pharmacovigilance  system 
for  collecting  information  about 
adverse  reactions  to  medicinal 
product&  in  human  beinga  and  for  the 
scientific  evaluation  of  such 
information. 
In  order  to  ensure  the  adoption  of 
appropriate  regulatory  decisions 
concerning  the  continued 
authorization  of  medicinal  products 
within  the  Community,  having  regard 
to  in  format ion  obtained  about 
adverse  react ions  to  medicinal 
products  under  practical  conditions 
of  use,  Member  States  shall 
establish a  pharmacovigilance  system 
for  collecting  information  about 
adverse  react ions  to  medicinal 
products  in  human  beings  and  for  the 
scientific  evaluation  of  such 
information,  such  that  the 
information  about  adverse  reactions 
is  systematically  related  to  the 
information  on  the  consumption  of 
medicinal  products. 
i - 30  -
Original  Text  Amendment  to  the  proposal 
Article  29b  unchanged 
Article  29c  points  (a)  and  (b)  unchanged 
Article  29c  point  c 
(c)  ensuring . that  any  request  from 
the  competent  authority  for  the 
provision  of  additional 
information  necessary  for  the 
evaluation  of  the  benefits  and 
risks of a  medicinal  product  ts 
answered  fully  and  promptly, 
i ncl udi ng  the  provi s.ion  of 
information  about  the  volume'of 
sales  or  prescriptions  for  the 
medicinal  product  conce~ned,. 
where  relevant. 
(c)· ensuring  that  any  request  from 
th·e  competent  authority  for  the 
provision  of  additional 
information  necessary  for  the 
evaluation  of  the  benefits  and 
risks  of a medicinal  product  is 
answered  fully  and  promptly, 
including:  the  pr.ovision  of 
information  a,bout  the  volume  of  ji 
sales· or  pre-scriptions  for  the  . 
medicinal  product  concerned. 
Articles  29d,  29e  and  29f  unchanged 
Article  29g 
In  order  to  facilitate  the  exchange 
of  information  about 
pharmacovigilance  within  the 
Community,  the  Agency  shall,  in 
consultation  with  Member  States,  the 
commission  and  the  interested 
parties,  draw  up  detailed  guidance 
on  the  collection,  verification  and 
presentation.  of  adverse  reaction 
reports. 
In  order  to  facilitate  the  exchange 
of  information  about 
pharmacovigilance  within  the 
Community,  the  Commission  shall,  in 
consultation with the Agency  and  the 
interested parties,  draw  up detailed 
guidance  on  the  collection, 
verification  and  presentation  of 
adverse  reaction  reports.  Such 
guidance shall  take  into account  the 
format  used  by  the  World  Health 
Organization. 
Article  29h 
Where  as  a  result  ot  the  evaluation 
ot  adver•e  reaction  reports,  a 
Member  State  ia  considering  amending 
the  terms  of  a  marketing 
authorization  or  ita  auapenaion  or 
withdrawal,  it  shall  forthwith 
inform the Agency. 
In  case of urgency,  the Member State concerned may 
suspend the marketing of  a medicinal product, provided 
the Agency  is  informed at the latest on the following 
working day.' 
Where  as  a  result  of  the  evaluation 
of  adverse  reaction  reparts,  a 
Member  State is considering amending 
the  terms  of  a  marketing 
authorizat-ion  or  its  suspension  or 
withdrawal,  it  shall  forthwith 
inform  the  Agency  and  the holder  of 
the marketing  authorization. 
In case of urgency,  the Member State concerned may 
suspend the marketing of a medicinal product, provided 
the Agency  is  informed at the latest  o~ the following 
working day.' 
Articles  4  and  5  unchanged - 31  -
3. 
Amendment  to  the  proposal  for  a 
COUNCIL  DIRECTIVE  SYN  311 
amending  Directives  81/851/EEC  and  81/852/EEC 
in  respect  of  veterinary medicinal  products 
Original  Text  Amendment  to  the  proposal 
Visas  and  recitals  unchanged 
Article  1  (1) 
(Directive  81/851/EEC,  Article  4  (1),  first  sub-paragraph) 
No  veterinary  medicinal  product  may 
be  placed  on  the  market  of  a  Member 
state  unless  an  authorization  has 
been  issued  by  the  competent 
authority  of  that  Member  State or  by 
the Community. 
No  veterinary  medicinal  product  may 
be  placed  on  the  market  of  a  Member 
State  unless  an  authorization  has 
been  obtained  in  accordance  with 
Community  rules. 
Articles  1  (2)  and  1  (3)  unchanged 
Article  1  (4)  Directive  81/851/EEC,  Article  5b 
Third  paragraph,  new 
Before  a  veterinary  medicinal 
product  is  placed  on  the  market  the 
competent  authorities  shall  forward 
to  the  European  Agency  for  the 
Evaluation  of  Medicinal  Products  a 
copy  of  the  decision  together  with 
the  summary  of  the  product 
characteristics  referred  to  in  this 
Article.  The  Agency  shall give  the 
authorized  veterinary  medicinal 
product  a  European  Register  number 
which  shall  be  marked  on  the 
packaging. 
Article  1(5) 
(Directive  81/851/EEC  Article  8,  first  paragraph) 
•.  Hember  States  shall  take  all 
appropriate  measures  to  ensure  that 
the  procedure  for  granting  an 
authorization  to  place  a  medicinal 
product  on  the  market  is  completed 
within  2l0  days  of  the  date  of 
submitting  the application. 
1.  Hember  States  shall  take  all 
appropriate  meaeuree  to  ensure  that 
the  procedure  for  granting  an 
authorizati.on  to  place  a  medi.cinal 
product  on  the  market  is  completed 
within  140  days  of  the  date  of 
Hubmitting  the application. 
paragraph  2  unchanged 
Articles  1  (6)  and  1  (7)  unchanged 
\ 
\ 
\ Original  Text  Amendment  to  the  proposal 
Article  1  (8) 
<Directive  81/851/EEC  Article  15  paragraph  1  ) 
I. Authorization  shall  be  valid  for 
five  years  and  may  be  renewable  for 
five-yea~ pe~iods,  on  application  by 
the  holder.  at  least  three  months 
before  the expiry date. 
I.  Authorization  shall  be  valid  for 
five  years  and  may  be  renewable  for 
iive-year periods,  on. application  by 
the  holder  at  least  three  months 
before  the  expiry  date  and  after 
consideration  of  a 
dossier  containing  up-to..:.date 
information  on  pharmacovigilance. 
paragraph  2  unchanged 
Article  1  (9)  (Directive  81/851/EEC  Chapter  IV) 
Ar~icles  16  - 19  proposal  unchanged 
Article  20  first  paragraph 
The  Member  States  .Q!:  the  Commission 
may,  in  specific  cases  where  the 
interest&  of  the  Community  are 
involved,  refer  the  matter  to  the 
committee  tor  the  application  of  the 
procedure  laid  down  in  Article  21 
be!ore  reaching  a  decision  on  a 
raq.ueat  for  a  marketing 
authorization  or  on  the  suspension 
or  revocation  of  an  authorization, 
or  on  any  other  amendment  to  the 
terms  of  a  marketing  ·authorization 
.which  appears  necessary,  in 
particular  to  take  account  of  the 
information  collected  in  accordance 
with Chapter VIa  of this Directive. 
The  Member  States,  the Commission or 
the  applicant  himself  may,  in 
specific  cases  where  the  interests 
of  the  Community  are  involved, 
refer  the  matter  to  the  Comit6  for 
the  application  of  the  procedure 
laid  down  in  Article  21  before 
reaching  a  decision  on  a  request  for 
a  marketing  authorization or  on  the 
suspension  or  revocation  of  an 
authorization,  or  on  any  other 
amendment  to  the  terms  of  a 
mar kat ing  au.thor ization  which 
appears  necessary,  in  particular  to 
take  account  of  the  information 
co ll  acted  in  accordance  with 
Chapter VIa of this Directive. 
Article  20  paragraphs  2  and  3  unchanged 
Article  21  - 23b  unchanged 
Article  23c 
1.  The  A9ency  ehall  publish  !ill  1.  The  Agency  shall  publish  ~ 
biennial  report  on  th~ operation  of 
the  procedures  laid  down  in  this 
Chapter.  and  shall  forward  it  for 
information  to  the  European 
Parliament  and  the Council. 
annual  report 
the  procedures 
Chapter. 
on  the 
laid 
operation  of 
down  in  this 
paragraph  2  unchanged 
Article  1  (10)  unchanged - 33  -
Original  Text  Amendment  to  the  proposal 
Article  1  (11) 
(Directive  81/851/EEC  Chapter  VIa) 
Article  42a 
In  order  to  ensure  the  adoption  of  appropriate 
regulatory  Decisions  concerning  the  continued 
authorization of veterinary medicinal produas within 
the Community, having regard to information obtained 
about  adverse  reactions  to  veterinary  medic;inal 
products under practical conditions of  use, the Member 
States shall establish a pharmacovigilance system for 
collecting  information  about  adverse  reactions  to 
veterinary  medicinal  productS  and  for  the  scientific 
evaluation of such information. 
In  order  to  ensure  the  adoption  of  appropriate 
regulatory  Decisions  concerning  the  continued 
authorization of veterinary medicinal prodtias within 
the Community, having regard to information obtained 
abo~t  adverse  reactions  to  veterinary  medicinal 
produas under practical conditions of  usc, the Member 
States shall establish a pharmacovigilance system for 
collecting  information  about  adverse  reactions  to 
veterinary  medicinal  productS  and  for  the  scientific 
evaluation of such information  s u c h  t  h a t  t he 
information· about  adverse  reactions 
is  systematically  related  to  the 
information  on  the  consumption  of 
medicinal  products. 
Article  42b  unchanged 
Articie  42c  points  (a)  and  (b)  unchanged 
Article  42cpoint  (c) 
(c)  ensuring  that  any  request  from  the  competent 
authority  for  the  provision  of  additional 
information  necessary  for  the evaluation of the 
benefits and risks of a  veterinary medicinal product 
is  answered  fully  and  promptly,  including  the 
provision of information about the volume of  sales 
for the veterinary medicinal  product concerned, 
.wbcR rdeyant 
(c)  ensuring  that  any  request  from  the  competent 
authority  for  the  provision  of  add:itional 
information  necessary  for  the evaluation of the 
benefits and risks of  a veterinary medicinal product 
is  answered  fully  and  promptly,  including  the 
provision of  information about the volume of  sales 
for the veterinary medicinal  product concerned., 
Articles  42d,  42e,  and  42f  unchanged 
Article  42g 
In  order  to  facilitate  the  exchange 
of  information  about 
pharmacovigilance  within  the 
Community,  the  Agency  shall,  in 
consultation  with  Member  States,  the 
Commission  and  the  interested 
parties,  draw  up  detailed  guidance 
on  the  collection,  verification  and 
presentation.  of  adverse  reaction 
reports. 
In  order  to  facilitate  the  exchange 
of  information  about 
pharmacovigilance  within  the 
Community,  the  Commission  shali,  in 
consultation with  the  Agency  and  the 
interested parties,  draw  up detailed 
guidance  on  the  collection, 
verification  and  presentation  of 
adverse  reaction  reports.  Such 
guidance shall take  into account  the 
format  used  by  the  World  Health 
Organi%.ation. - 34  -
Original  Text ·  Amendment  to  the  proposal. 
Article  42h 
Where  as  a  result  of  the  evaluation 
of  adver•e  reaction  reports,  a 
Member  State  is  considering  amending 
the  terms  of  a  .market~ng 
authorization  or  ita  suspension· qr 
withdrawal,  it  ahall  forthwith 
inform the Agency. 
In  case of urgency,  the Member State concerned may 
suspend the marketing of a medicinal product, provided 
the Agency  is  informed at the latest on the following 
working day.' 
Where  as  a  result  of  the  evaluation 
of.  adverse  reaction  reports,  a 
Member  State is considering amending 
the  terms  of  a  marketing 
authorization  or  ita  suspension  or 
withdra...,al,  it  shall  forthwith 
inform  the  Agency  and  the  holder of 
the marketing  authorization. 
.  ·- ' 
In  caSe of urgency,  the  Member State concerned may 
suspend the marke~ing  of  a medicinal product, provided 
the Agency  is  informed at the latest on the following 
working day.' 
Arti~les 2  - 4  unchanged 
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